ClinicalTrials.gg
TerminatedNCT00251953Updated Apr 22, 2009

GALLANT 8 Tesaglitazar Add-on to Metformin

A Phase 3 interventional study of Tesaglitazar and Metformin in Type 2 Diabetes, sponsored by AstraZeneca. Terminated at 107 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-04-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was terminated
The development program has been terminated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
555
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. tesaglitazar · Diabetes Mellitus, Type 2.

Enrollment
7th of 15
555 · median 500
Started
2004
with 6 others
Phase 3
11 of 15
none open now
Registered
6th of 15
by date
Lead sponsor
15 of 15
AstraZeneca

Among the 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 7 that started in 2004, is one of 11 in phase 3, and was the 6th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About tesaglitazar

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing tesaglitazar in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This is a 24-week randomized double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 mg and 1 mg) given as add-on therapy to metformin in patients with type 2 diabetes, not adequately controlled on optimized metformin treatment and on diet/lifestyle advice during the titration and run-in period. The study comprises a 2-week enrollment period, 6 week placebo metformin titration period, 2-week single-blind run-in period, followed by a 24-week double blind treatment period and a 3-week follow-up period

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of a written
  • Men or women who are >=18 years of age
  • Female patients: , hysterectomized, or if of , using a reliable method of
  • Diagnosed with type 2 diabetes
  • Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • heart failure Class III or IV
  • Treatment with chronic insulin
  • History of or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
  • History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
  • Creatinine levels above twice the normal range
  • Creatine kinase above 3 times the
  • Received any product in other clinical studies within 12 weeks
  • Any abnormality identified on physical examination, laboratory tests or , which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
555 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)

Secondary outcomes

  1. Changes in the following variables from baseline to the end of the randomized treatment period:

  2. Fasting plasma glucose (FPG), insulin, proinsulin and C-peptide

  3. Insulin sensitivity by assessment of change in the calculated variable homeostasis assessment model

  4. Lipid parameters (triglyceride [TG], total cholesterol, high-density lipoprotein cholesterol [HDL C], non-HDL C, low-density lipoprotein cholesterol [LDL C], apolipoproteins [Apo] A-I, Apo B, Apo CIII, free fatty acids, lipoprotein particle size and c

  5. C-reactive protein, LDL C/HDL C ratio and Apo B/Apo A-I ratio

  6. FPG, homeostasis assessment model, insulin, proinsulin, C-peptide

  7. Tumor necrosis factor-alpha, intracellular adhesion molecule-1

  8. Fibrinogen

  9. Urinary albumin excretion

  10. Waist/hip ratio

  11. Responder analyses for HbA1c, FPG, TG, HDL C, total cholesterol, non HDL C and LDL C according to pre-specified values

  12. Proportion of patients reaching pre-specified target levels for HbA1c, FPG, TG, HDL C, non-HDL C and LDL C

  13. Pharmacokinetics of tesaglitazar

  14. Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination

07

Study locations

107 sites
  • Research Site
    Adelaide, Australia
  • Research Site
    Brisbane, Australia
  • Research Site
    Cairns, Australia
  • Research Site
    Geelong, Australia
  • Research Site
    Melbourne, Australia
  • Research Site
    Perth, Australia
  • Research Site
    Sydney, Australia
  • Research Site
    Coquitlam, British Columbia, Canada
  • Research Site
    Winnipeg, Manitoba, Canada
  • Research Site
    St. John's, Newfoundland and Labrador, Canada
  • Research Site
    Etobicoke, Ontario, Canada
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Hastings, Ontario, Canada
  • Research Site
    Kingston, Ontario, Canada
  • Research Site
    North York, Ontario, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Smith Falls, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Chomedey-Laval, Quebec, Canada
  • Research Site
    Laval, Quebec, Canada
  • Research Site
    Montréal, Quebec, Canada
  • Research Site
    Helsinki, Finland
  • Research Site
    Hämeenlinna, Finland
  • Research Site
    Joensuu, Finland
  • Research Site
    Kouvola, Finland
  • Research Site
    Kuopio, Finland
  • Research Site
    Mikkeli, Finland
  • Research Site
    Oulu, Finland
  • Research Site
    Salo, Finland
  • Research Site
    Tampere, Finland
  • Research Site
    Vantaa, Finland
  • Research Site
    Aschaffenburg, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Mannheim, Germany
  • Research Site
    Nürberg, Germany
  • Research Site
    Rotenburg/Fulda, Germany
  • Research Site
    Bangalore, India
  • Research Site
    Hyderabad, India
  • Research Site
    New Delhi, India
  • Research Site
    Arenzano, Italy
  • Research Site
    Chiavari (GE), Italy
  • Research Site
    Chieri, Italy
  • Research Site
    Desio, Italy
  • Research Site
    Firenze, Italy
  • Research Site
    Gubbio, Italy
  • Research Site
    Marsala, Italy
  • Research Site
    Messina, Italy
  • Research Site
    Milano, Italy
  • Research Site
    Monteccio Emilia, Italy
  • Research Site
    Napoli, Italy
  • Research Site
    Padova, Italy
  • Research Site
    Perugia, Italy
  • Research Site
    Pescara, Italy
  • Research Site
    Piacenza, Italy
  • Research Site
    Pistoia, Italy
  • Research Site
    Reggio Calabria, Italy
  • Research Site
    Reggio Emilia, Italy
  • Research Site
    Rho, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Scandiano, Italy
  • Research Site
    Udine, Italy
  • Research Site
    Kubang Kerian, Kota Bharu, Malaysia
  • Research Site
    Kuala Lumpur, Malaysia
  • Research Site
    Cebu City, Philippines
  • Research Site
    Quezon City, Philippines
  • Research Site
    Singapore, Singapore
  • Research Site
    Borås, Sweden
  • Research Site
    Dalby, Sweden
  • Research Site
    Göteborg, Sweden
  • Research Site
    Höganäs, Sweden
  • Research Site
    Kungsör, Sweden
  • Research Site
    Malmö, Sweden
  • Research Site
    Mölndal, Sweden
  • Research Site
    Oskarshamn, Sweden
  • Research Site
    Skene, Sweden
  • Research Site
    Skrivarp, Sweden
  • Research Site
    Stenungsund, Sweden
  • Research Site
    Uppsala, Sweden
  • Research Site
    Ängelholm, Sweden
  • Research Site
    Aberdeen, United Kingdom
  • Research Site
    Aldershot, United Kingdom
  • Research Site
    Atherstone, United Kingdom
  • Research Site
    Barry, United Kingdom
  • Research Site
    Bath, United Kingdom
  • Research Site
    Bexhill-on-Sea, United Kingdom
  • Research Site
    Birmingham, United Kingdom
  • Research Site
    Bolton, United Kingdom
  • Research Site
    Cardiff, United Kingdom
  • Research Site
    Chippenham, United Kingdom
  • Research Site
    Coventry, United Kingdom
  • Research Site
    Dundee, United Kingdom
  • Research Site
    Edinburgh, United Kingdom
  • Research Site
    Glasgow, United Kingdom
  • Research Site
    Harrow, United Kingdom
  • Research Site
    Hastings, United Kingdom
  • Research Site
    Leeds, United Kingdom
  • Research Site
    Liverpool, United Kingdom

Showing the first 100 of 107 sites across 11 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2005
First posted
Nov 11, 2005
Start
Jul 2004
CompletionActual
Mar 2006
Last update
Apr 22, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00251953
Lead sponsor
AstraZeneca
First posted
Nov 11, 2005
Start date
Jul 2004
Completion
Mar 2006
Last update
Apr 22, 2009

Study contacts

AstraZeneca Galida Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tesaglitazar · Metformin

Start the discussion